Paxlovid (Nirmatrelvir/ritonavir): An Innovative Method Method for Treating Covid-19?

Author(s)	Prathamesh D. Wankhade, S. G. Jawarkar, Dr. Monika P. Jadhao
Country	India
Abstract	Nirmatrelvir Ritonavir 3-c like protease COVID-19 SARS-COV-2Despite the need for innovative, efficient treatment for the Covid Pandemic, there is currently no curative regimen available, leaving patients to rely on supportive and general treatments. The 3C like-protease (3CLpro) and the main protease (Mpro), two SARS-COV-2 proteins, have been identified as potential targets for antiviral medications. The Mpro might be viable therapeutic target since it plays a significant role in both the pathogenesis of the virus and processing. Nirmatrelvir, an antiviral medication, prevents SARS-CoV-2 from reproducing by blocking Mpro. Another HIV protease inhibitor, ritonavir, was coupled with nirmatrelvir to develop. Ritonavir inhibits the cytochrome P450 3A metabolizing enzyme, extending the half-life of nirmatrelvir and serving as pharmacological enhancer. Despite major modification of the SARS-COV-2 viral genome, nirmatrelvir still has strong antiviral effectiveness against contemporary coronavirus strains. However, there are still a number of open issues. The effectiveness of nirmatrelvir and ritonavir in treating SARS-COV-2 infection, as well as their safety and potential adverse effects are discussed in this review of literature.
Field	Chemistry > Pharmacy
Published In	Volume 6, Issue 2, March-April 2024
Published On	2024-04-10
DOI	https://doi.org/10.36948/ijfmr.2024.v06i02.14726

About IJFMR Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics Peer Review & Plagiarism	Join as a Reviewer Editors & Reviewers Reviewer Referral Program Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us		+91-9687-828-838	editor@ijfmr.com

International Journal For Multidisciplinary Research